{"disease":{"id":"ebv-associated-lymphoma","name":"ebv associated lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05978141","title":"A Registry for People With T-cell Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT07381738","title":"Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04902443","title":"Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":58,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06834373","title":"Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":41,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05507541","title":"TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06391814","title":"Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01)","phase":"NA","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"Ciusss de L'Est de l'Île de Montréal","has_results":false},{"nct_id":"NCT05882305","title":"KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial","phase":"EARLY_PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Kousai Bio Co., Ltd.","has_results":false},{"nct_id":"NCT02822495","title":"Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Atara Biotherapeutics","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}